Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Lymphoma, Non-Hodgkin 105Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84Lymphoma, Follicular 68Hodgkin Disease 54Burkitt Lymphoma 52Multiple Myeloma 51Lymphoma, B-Cell 51Recurrence 46Lymphoma, Mantle-Cell 46Leukemia, Myeloid, Acute 44Leukemia 37Neoplasms 35Hematologic Neoplasms 32Myelodysplastic Syndromes 29Lymphoma, B-Cell, Marginal Zone 26Waldenstrom Macroglobulinemia 22Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, T-Cell 18Lymphoma, T-Cell, Peripheral 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Leukemia, B-Cell 16Lymphoma, Large-Cell, Anaplastic 15Sarcoma 13Leukemia, Biphenotypic, Acute 13Mycosis Fungoides 11Melanoma 10Lymphoma, T-Cell, Cutaneous 10

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Classic Follicular Lymphoma × Lymphoid × 30 days × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡